Shrinking Big Pharma

Why building smaller manufacturing plants is the next big thing

weblead

Bigger isn’t always better. In fact, the growing trend in pharma is looking at ways to shrink the industry’s plant-floor footprint down.A few months ago, Amgen announced plans to build a new “next-generation” manufacturing facility in Rhode Island, which will be modeled on the company’s highly innovative plant in Singapore. What makes it cutting edge? Its smaller size. According to Amgen, its Singapore facility occupies about one-fifth the size of a traditional pharma plant but maintains a comparable level of output. It was also built in half the time and at a fraction of the price of a conventional plant ­— a new measure of efficiency Amgen intends to…

Full Story

Don't Miss These Pharma Manufacturing Exclusives

Fundamentals

On-demand, concise audio and powerpoint tutorials on the fundamental concepts of pharmaceutical manufacturing, process development, quality control and compliance.

Research Zone

A collection of news stories highlighting advances in medical science and pharmaceutical R&D.

Funny Pharm

Write a caption and win!

Aug15homepageBe sure to check out our newest cartoon created by award-winning artist Jerry King. He provides the artwork; you provide the funny caption!

Most Recent

  • The Clock is Ticking: How to Speed up Efforts to Meet Traceability Deadlines

    By Himanshu Jain, NTT DATA Healthcare and Life Sciences

    Starting November 2018, the U.S. Food and Drug Administration (FDA) will begin enforcing the requirement in the Drug Supply Chain Security Act (DSCSA) to include a product identifier on prescription drug packaging.2 The deadline for drugs coming from the EU is about two months later, on Feb. 9,…

    Full Story
  • Bringing Smart Instrumentation to Life Sciences

    By Kyle Knutson, Product Manager for Rosemount Pressure and Hygienic, Emerson Automation Solutions

    The life sciences industries in general and pharmaceutical manufacturing in particular are subject to a wide variety of regulations covering production techniques and equipment design. This isn’t exactly news to anyone in the business, but stop for a moment and consider what it means on a…

    Full Story
  • Pharma’s Reputational Tornado Zone

    By Dr. Nir Kossovsky, CEO, Steel City Re

    Reputational risk is often equated with the risk of negative media coverage and, by that definition, is simply a marketing challenge. But given its complexity, a more accurate way to define reputational risk is to consider it as the risk of economic damage from angry, frightened or disappointed…

    Full Story
  • API Sourcing: Your Questions Answered

    By Jan Batka, API sales director, Saneca Pharma

    What criteria should drug manufacturers consider when choosing API sourcing partners?Generally speaking, manufacturers need to think about the long-term stability of their partner. Can they offer sustained supply of a high-quality product at a competitive price and is their service flexible enough…

    Full Story
  • Less Space for Waste

    By Karen Langhauser, Chief Content Director

    "Single-use devices have clearly reached mainstream acceptance in the industry,” concluded BioPlan, after reviewing the results of their Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production.According to BioPlan’s survey, almost 90 percent of respondents continue…

    Full Story
  • Vendor Selection and Management From a Small Pharma Perspective

    By Gowri Sukumar, Associate Director, CMC and Regulatory Affairs, ESSA Pharmaceuticals.

    Running successful clinical trials is challenging for any company. With ever-increasing pressure among life science companies to develop treatments and medicines faster, more are outsourcing many of their core business processes.  With the level of outsourced pharmaceutical production exceeding 40…

    Full Story

Latest Products